Attached files

file filename
8-K - FORM 8-K - SURGALIGN HOLDINGS, INC.d917686d8k.htm

Exhibit 99.1

 

LOGO

Press Release

RTI Surgical Holdings, Inc.® Provides Business Updates

Jonathon Singer

Investor and Media Contact

jsinger@rtix.com

+1 877-343-6832

DEERFIELD, Ill., June 30, 2020 – RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today provided a business update in conjunction with releasing financial and operating results for the quarter ended March 31, 2020.

Business Update Highlights:

 

   

Scheduled special meeting of stockholders for July 15, 2020 to vote on sale of OEM business

 

   

Announced two senior leadership appointments and a new director to support transition to a pure-play global spine company

 

   

First quarter 2020:

 

   

Revenue of $73.7 million, up 5% compared to the first quarter of 2019

 

   

Net loss of $17.9 million, or $0.24 per common share

 

   

Adjusted EBITDA of $1.4 million, or 2% of revenue

“I am very proud of the actions taken by our entire organization over the last several months as we have navigated the COVID-19 pandemic while at the same time managing through the pending sale of the OEM business and a number of other headwinds,” said Camille Farhat, President and CEO, RTI Surgical. “The integrity, dedication, and talent of our people have enabled us to come out on the other side of this unique period in time ready to take advantage of the opportunities that exist in the Spine market for high-value surgical solutions.”

Farhat continued, “We view the recent disruption as transitory, and despite the uncertainty associated with COVID-19, we remain very confident in the long-term prospects of the Spine business. We are targeting double-digit long-term revenue growth with gross margins of 75% by executing on our strategy of build, innovate, and acquire. We are very excited about this next phase of RTI’s transformation.”

Annual Meeting and Special Meeting of Stockholders

The company will hold its annual meeting of stockholders on July 15, 2020. Among the matters to be considered and voted on at the Annual Meeting, which, as previously disclosed, will be combined with a special meeting of the stockholders, are the various proposals necessary to approve the transactions contemplated by the previously announced Equity Purchase Agreement, dated January 13, 2020, as amended, with Ardi Bidco Ltd., a Delaware corporation and an entity affiliated with Montagu Private Equity, LLP (the “Buyer”), pursuant to which the Buyer will acquire the OEM business of the Company by means of a sale of certain affiliates of the Company.


LOGO

Press Release

 

Spine Business Update

On June 10, 2020 The Company announced two senior leadership appointments to support its transition to a pure-play global spine company. Scott Durall joined RTI as Chief Commercial Officer, and Bryan Cornwall joined RTI as Executive Vice President, Research and Clinical Affairs, both effective June 15, 2020. Durall and Cornwall bring to RTI decades of commercial, operational and scientific expertise, and will support the Company’s ongoing focus on becoming a leader in the global spine market following the close of the pending sale of the OEM business. Please see our related press release for more detail on their backgrounds.

In addition, on June 1, Stuart F. Simpson joined the Board of Directors and was recently named Vice Chairman of the Board. Mr. Simpson brings decades of industry experience which will be valuable in supporting RTI’s strategy as a pure-play global spine company.

First Quarter 2020 Financial Results

RTI’s worldwide revenues for the first quarter of 2020 were $73.7 million, an increase of $3.7 million, or 5% compared with $70.0 million during the same period in the prior year. Gross profit for the first quarter of 2020 was $40.5 million, or 55% of revenues, a 7.0% increase compared to $37.9 million, or 54% of revenues, in the first quarter of 2019.

Net loss applicable to common shares was $17.9 million, or $0.24 per fully diluted common share in the first quarter of 2020, compared to net loss applicable to common shares of $9.4 million, or $0.14 per fully diluted common share in the first quarter of 2019.

Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA), for the first quarter of 2020 was $1.4 million, or 2% of revenues, compared with $7.0 million, or 10% of revenues for the first quarter of 2019. The decrease in Adjusted EBITDA was primarily driven by annualization of costs related to the Paradigm acquisition and incremental investment for the separation of the business to support the sale of the OEM business.

2020 Outlook

Due to the inability to estimate the size and impact of the COVID-19 pandemic on the Company’s operations and financial results, RTI Surgical Holdings, Inc. will not provide guidance for fiscal year 2020. We will continue to evaluate the COVID-19 pandemic on our operations and financial results and will provide additional information when we are more certain.

Conference Call

RTI will host a conference call and audio webcast at 9:00 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International), using conference ID 6346397. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com/investors. A replay of the conference call will be available on RTI’s website for one month following the call.


LOGO

Press Release

 

About RTI Surgical Holdings, Inc.

RTI Surgical Holdings is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, plastic surgery, spine, orthopedic and trauma procedures and are distributed in over 50 countries. RTI has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com. Connect with us on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are not guarantees of future performance and are based on certain assumptions including general economic conditions, as well as those within the Company’s industry, and numerous other factors and risks identified in the Company’s Form 10-K for the fiscal year ended December 31, 2019 and other filings with the SEC. Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Important factors that could cause actual results to differ materially from the anticipated results reflected in these forward-looking statements include risks and uncertainties relating to the following: (i) the risk of existing or potential litigation or regulatory action arising from the previously announced internal investigation and its findings or from the failure to timely file the Form 10-K; (ii) the identification of control deficiencies, including material weaknesses in internal control over financial reporting and the impact of the same; (iii) potential reputational damage that the Company has or may suffer as a result of the ultimate findings of the investigation; (iv) general worldwide economic conditions and related uncertainties; (v) the anticipated impact of the COVID-19 novel coronavirus pandemic and the Company’s attempts at mitigation; (vi) the failure by the Company to identify, develop and successfully implement immediate action plans and longer-term strategic initiatives; (vii) our ability to continue production; (viii) the reliability of our supply chain; (ix) our ability to meet obligations under our debt or material agreements; (x) the duration of decreased demand for our products; (xi) our ability to continue to recall furloughed employees; (xii) whether or when the demand for procedures will increase; (xiii) the Company’s access to adequate operating cash flow, trade credit, borrowed funds and capital to fund its operations and pay its obligations as they become due, including the impact of adverse trends or disruption in the global credit and equity markets; (xiv) our financial position and results, total revenue, product revenue, gross margin,


LOGO

Press Release

 

and operations; (xv) the risk that the Company may be unable to obtain shareholder approval for the proposed transaction; (xvi) the risk that a condition to the closing of the proposed transaction may not be satisfied; (xvii) the risk that the occurrence of an event that could give rise to termination of the definitive agreement; (xviii) the risk that shareholder litigation in connection with the proposed transaction may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability; (xix) the timing to consummate the proposed transaction; (xx) the effect of the announcement or disruption from the proposed transaction making it more difficult to retain and hire key personnel and maintain relationships with customers, suppliers and other third parties; (xxi) the diversion of management time and attention on the proposed transaction; (xxii) the effect and timing of changes in laws or in governmental regulations; and (xxiii) other risks described in our public filings with the SEC. These factors should be considered carefully and undue reliance should not be placed on the forward-looking statements. Each forward-looking statement in this communication speaks only as of the date of the particular statement. Copies of the Company’s SEC filings may be obtained by contacting the Company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov. We undertake no obligation to update these forward-looking statements except as may be required by law.


LOGO

Press Release

 

RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share data)

 

     For the Three Months Ended  
     March 31,  
     2020     2019  

Revenues

   $ 73,726     $ 70,021  

Costs of processing and distribution

     33,273       32,134  
  

 

 

   

 

 

 

Gross profit

     40,453       37,887  
  

 

 

   

 

 

 

Expenses:

    

Marketing, general and administrative

     39,217       32,116  

Research and development

     4,282       4,336  

Asset impairment and abandonments

     1,879       15  

Other general expenses

     3,436       —    

Transaction and integration expenses

     9,280       8,957  
  

 

 

   

 

 

 

Total operating expenses

     58,094       45,424  
  

 

 

   

 

 

 

Operating loss

     (17,641     (7,537
  

 

 

   

 

 

 

Total other expense - net

     (3,761     (1,504
  

 

 

   

 

 

 

Loss before income tax benefit (expense)

     (21,402     (9,041

Income tax benefit (expense)

     3,539       (310
  

 

 

   

 

 

 

Net loss

     (17,863     (9,351
  

 

 

   

 

 

 

Convertible preferred dividend

     —         —    
  

 

 

   

 

 

 

Net loss applicable to common shares

   $ (17,863   $ (9,351
  

 

 

   

 

 

 

Net loss per common share - basic

   $ (0.24   $ (0.14
  

 

 

   

 

 

 

Net loss per common share - diluted

   $ (0.24   $ (0.14
  

 

 

   

 

 

 

Weighted average shares outstanding - basic

     75,847,046       65,675,203  
  

 

 

   

 

 

 

Weighted average shares outstanding - diluted

     75,847,046       65,675,203  
  

 

 

   

 

 

 


LOGO

Press Release

 

RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES

Reconciliation of Revenues to Adjusted Gross Profit

(Unaudited, in thousands)

 

     For the Three Months Ended  
     March 31,  
     2020     2019  

Revenues

   $ 73,726     $ 70,021  

Costs of processing and distribution

     33,273       32,134  
  

 

 

   

 

 

 

Gross profit, as reported

     40,453       37,887  

Inventory write-off

     48       —    

Inventory purchase price adjustment

     878       —    
  

 

 

   

 

 

 

Non-GAAP gross profit, adjusted

   $  41,379     $  37,887  
  

 

 

   

 

 

 

Non-GAAP gross profit percentage, adjusted

     56.1     54.1


LOGO

Press Release

 

RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES

Reconciliation of Net Loss Applicable to Commons Shares to Adjusted EBITDA

(Unaudited, in thousands)

 

     For the Three Months Ended  
     March 31,  
     2020     2019  

Net loss applicable to common shares

   $  (17,863   $  (9,351

Interest expense, net

     3,515       1,473  

Provision for income taxes

     (3,539     310  

Depreciation

     1,766       3,443  

Amortization of intangible assets

     473       957  
  

 

 

   

 

 

 

EBITDA

     (15,648     (3,168

Reconciling items impacting EBITDA

    

Preferred dividend

     —         —    

Non-cash stock based compensation

     1,310       1,163  

Foreign exchange gain (loss)

     246       31  

Other reconciling items *

    

Inventory write-off

     48       —    

Inventory purchase price adjustment

     878       —    

Other general expenses

     3,436       —    

Asset impairment and abandonments

     1,879       —    

Transaction and integration expenses

     9,280       8,957  
  

 

 

   

 

 

 

Adjusted EBITDA

   $ 1,429     $ 6,983  
  

 

 

   

 

 

 

Adjusted EBITDA as a percent of revenues

     1.9     10.0
  

 

 

   

 

 

 

 

*

See explanations in Use of Non-GAAP Financial Measures section later in this release.


LOGO

Press Release

 

RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES

Reconciliation of Net Income (Loss) Applicable to Common Shares and Net Income (Loss) Per Diluted Share to

Adjusted Net Income Applicable to Common Shares and Adjusted Net Income Per Diluted Share

(Unaudited, in thousands except per share data)

 

     For the Three Months Ended  
     March 31, 2020     March 31, 2019  
     Net
Income (Loss)
Applicable to
Common Shares
    Amount
Per Diluted
Share
    Net
Income (Loss)
Applicable to
Common Shares
    Amount
Per Diluted
Share
 

As reported

   $  (17,863   $  (0.24   $  (9,351   $  (0.14

Asset impairment and abandonments

     1,879       0.02       —         —    

Inventory purchase price adjustment

     878       0.01       —         —    

Other general expenses

     3,436       0.05       —         —    

Inventory write-off

     48       0.00       —         —    

Transaction and integration expenses

     9,280       0.12       8,957       0.14  

Tax effect on adjustments

     —         —         617       0.01  
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted*

   $  (2,342   $  (0.03   $ 223     $ 0.00  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

*

See explanations in Use of Non-GAAP Financial Measures section later in this release.

Amount Per Diluted Share may not foot due to rounding.


LOGO

Press Release

 

Use of Non-GAAP Financial Measures

To supplement the Company’s unaudited condensed consolidated financial statements presented on a GAAP basis, the Company discloses certain non-GAAP financial measures that exclude certain amounts, including EBITDA, Adjusted EBITDA and Adjusted Net Income Applicable to Common Shares. The calculation of the tax effect on the adjustments between GAAP net loss applicable to common shares and non-GAAP net income applicable to common shares is based upon our estimated annual GAAP tax rate, adjusted to account for items excluded from GAAP net loss applicable to common shares in calculating Adjusted Net Income Applicable to Common Shares-Diluted. A reconciliation of the non-GAAP financial measures to the corresponding GAAP measures is included in the tables listed above.    

The following are explanations of the adjustments that management excluded as part of the non-GAAP measures for the three months ended March 31, 2020 and 2019. Management removes the amount of these costs including the tax effect on the adjustments from our operating results to supplement a comparison to our past operating performance.

2020 Asset impairment and abandonments – These costs relate to asset impairment and abandonments of certain long-term assets within the Spine asset group.

2020 Other general expenses – These costs relate to consulting and legal fees and settlement expenses incurred as a result of the restatement, regulatory and related activities in 2020.

2020 Transaction and integration expenses – These costs relate to transaction and separation expenses due the Sale of OEM in 2020.

2020 Inventory purchase price adjustment – These costs relate to the purchase price effects of acquired Paradigm inventory that was sold during the three months ended March 31, 2020.

2019 Transaction and integration expenses – These costs relate to acquisition and integration expenses due to the purchase of Paradigm in 2019.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

EBITDA, Adjusted EBITDA and Adjusted Net Income Applicable to Common Shares should not be considered in isolation, or as a replacement for GAAP measures.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting EBITDA, Adjusted EBITDA and Adjusted Net Income Applicable to Common Shares in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making.


LOGO

Press Release

 

The Company further believes that providing this information better enables the Company’s investors to understand the Company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.


LOGO

Press Release

 

RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Revenues

(Unaudited, in thousands)

 

     For the Three Months Ended  
     March 31,  
     2020      2019  

Revenues:

  

Spine

   $  27,109      $  24,377  

OEM

     46,617        45,644  
  

 

 

    

 

 

 

Total revenues

   $ 73,726      $ 70,021  
  

 

 

    

 

 

 


LOGO

Press Release

 

RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited, in thousands)

 

     March 31,     December 31,  
     2020     2019  
Assets     

Cash

   $ 6,557     $ 5,608  

Accounts receivable - net

     54,921       59,288  

Inventories - net

     126,760       124,149  

Prepaid and other assets

     8,422       6,769  
  

 

 

   

 

 

 

Total current assets

     196,660       195,814  

Non-current inventories - net

     5,891       6,637  

Property, plant and equipment - net

     70,716       69,890  

Goodwill

     55,384       55,384  

Other assets - net

     16,419       16,784  
  

 

 

   

 

 

 

Total assets

   $ 345,070     $ 344,509  
  

 

 

   

 

 

 

Liabilities and Stockholders’ Equity

    

Accounts payable

   $ 38,520     $ 30,126  

Accrued expenses and other current liabilities

     43,364       36,085  

Current portion of long-term obligations

     175,673       174,177  
  

 

 

   

 

 

 

Total current liabilities

     257,557       240,388  

Long-term liabilities

     3,633       3,147  
  

 

 

   

 

 

 

Total liabilities

     261,190       243,535  

Preferred stock

     66,456       66,410  

Stockholders’ equity:

    

Common stock and additional paid-in capital

     494,465       493,372  

Accumulated other comprehensive loss

     (7,999     (7,629

Accumulated deficit

     (469,042     (451,179
  

 

 

   

 

 

 

Total stockholders’ equity

     17,424       34,564  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 345,070     $ 344,509  
  

 

 

   

 

 

 


LOGO

Press Release

 

RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited, in thousands)

 

     For the Three Months Ended  
     March 31,  
     2020     2019  

Cash flows from operating activities:

    

Net loss

   $ (17,863   $ (9,351

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

    

Depreciation and amortization expense

     2,239       4,400  

Stock-based compensation

     1,310       1,163  

Amortization of deferred revenue

     (1,188     (1,292

Other items to reconcile to net cash used in operating activities

     22,018       (10,477
  

 

 

   

 

 

 

Net cash provided by (used in) operating activities

     6,516       (15,557
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchases of property, plant and equipment

     (5,084     (3,477

Patent and acquired intangible asset costs

     (286     (328

Acquisition of Paradigm Spine

     —         (99,921
  

 

 

   

 

 

 

Net cash used in investing activities

     (5,370     (103,726
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from long-term obligations

     —         115,000  

Payments of debt issuance costs

     —         (729

Payments for treasury stock

     (193     —    

Other financing activities

     20       156  
  

 

 

   

 

 

 

Net cash (used in) provided by financing activities

     (173     114,427  
  

 

 

   

 

 

 

Effect of exchange rate changes on cash and cash equivalents

     (24     (50
  

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     949       (4,906

Cash and cash equivalents, beginning of period

     5,608       10,949  
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 6,557     $ 6,043